Site Search
Professionals 626 results
Capabilities 83 results
Industry
The medical device industry is currently undergoing monumental change—from supply chain challenges to disruptive technologies and economic fluctuations. To pave the way for a more accessible and innovative healthcare landscape—including advances in wearables, implants, diagnostics, mobility, drug delivery—the evolving and expansive medical device industry faces wide-ranging legal needs. Clients in this sector can tap the remarkable depth and breadth of our sector-focused and skilled attorneys in the U.S. and abroad. Our Healthcare & Life Sciences Industry Group engages clients at all points in the product development life cycle to provide sound advice and practical solutions regardless of the client’s size or the complexity of their need. We help clients navigate today’s complex regulatory landscape, defend products and reputations in the face of high-profile product liability and mass tort claims, protect innovative intellectual property (IP), and leverage cross-border experience to advise on commercial transactions.
Industry
Winston’s financial crimes compliance lawyers have been providing regulatory compliance counseling and enforcement services related to the Bank Secrecy Act (BSA), the Anti-Money Laundering Act of 2020 (AML), and countering the financing of terrorism (CFT) policy for decades. We also have experience with international AML matters, including in the EU and with respect to Financial Actions Task Force (FATF) recommendations.
Industry
Experience 176 results
Experience
|March 4, 2026
End of the Line: Winston Wins Unanimous Supreme Court Victory Against NJ Transit
In a unanimous decision authored by Justice Sotomayor, the U.S. Supreme Court held that NJ Transit is not an arm of the State of New Jersey and therefore is not entitled to sovereign immunity. The ruling means that plaintiffs injured by NJ Transit outside of New Jersey—such as in Pennsylvania and New York—may pursue claims in the courts of the states where their injuries occurred. The court adopted Winston’s position that state-created corporations that are formally liable for their own judgments are not arms of the state, reversing the Pennsylvania Supreme Court’s dismissal of Cedric Galette’s negligence suit while affirming the New York Court of Appeals’ decision allowing Jeffrey Colt’s case to proceed.
Experience
|February 22, 2026
Winston & Strawn LLP Paris advised the Compagnie Européenne de Garantie et Caution (CEGC, BPCE Group) financial creditors on the adoption of Réalités’ recovery plan by the Nantes Commercial Court.
Experience
|February 6, 2026
Winston Represented ETi Gida in Acquisition of TRUBAR
A Winston deal team, led by Tim Kincaid, Brad Vaiana and Ben Popeck, represented Turkish snack company ETI Gida Sanayi ve Ticaret Anonim Sirketi (ETi Gida) in its acquisition of Miami-based TRUBAR, a popular nutrition bar known for dessert-inspired flavor and clean ingredients.
Insights & News 5,833 results
Seminar/CLE
|March 25, 2026
Sanctions, Arbitration, and Cross-Border Enforcement: Complex Intersections in Practice
We are pleased to host an exclusive panel session during Paris Arbitration Week, exploring the complex intersections of sanctions regimes, international arbitration, and cross-border enforcement. This program combines real-world case insights with comparative perspectives to help practitioners navigate today’s challenging global legal landscape.
Webinar
|March 19, 2026
New Perspectives on Venezuela: On-the-Ground Insights and Direct Foreign Investment Outlook
Please join us for the next session in our webinar series on Venezuela’s evolving economic and legal landscape, featuring a special presentation by Venezuelan lawyers Pedro Urdaneta and Miguel Rivero, partners at LEGA Abogados, who will share valuable on-the-ground insights. Winston & Strawn partners Cari Stinebower and Carl Fornaris will moderate the conversation, and time will be set aside to take questions from the audience.
In the Media
|March 10, 2026
|2 Min Read
Winston & Strawn’s New Miami Office Draws Headlines
Winston’s move to its new Miami office has drawn attention from local and industry media, including Daily Business Review, South Florida Business Journal, and more. The coverage highlights how the firm’s move to the 17thand 18thfloors at 200 S. Biscayne Boulevard reflects the firm’s ongoing commitment to investing in its clients, its people, and the communities in which it operates.
Other Results 84 results
Law Glossary
What Is the Standard for the FDA to Grant a Generic Drug License?
An Abbreviated New Drug Application (ANDA) must contain evidence that the proposed generic drug product is bioequivalent to the reference drug.
Law Glossary
What Is the Approval Process for Generic Drugs?
Approval for generic drugs are governed by the Hatch-Waxman Act. The Hatch-Waxman Act provides the framework for an applicant to demonstrate that its proposed generic product is bioequivalent to the brand-name drug.
Law Glossary
Generic drugs are typically small, chemically synthesized molecules—that is, they have relatively low molecular weights, frequently less than 1000 daltons and usually between 300 and 700 daltons. Biosimilars, on the other hand, are typically substantially larger in molecular weight than small molecule drugs. For example, a monoclonal antibody—a typical biosimilar drug—generally has a molecular weight in excess of 150,000 daltons. In contrast, aspirin—a typical small molecule drug—has a molecular weight of 180 daltons.